F. Majois

482 total citations
28 papers, 350 citations indexed

About

F. Majois is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, F. Majois has authored 28 papers receiving a total of 350 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 8 papers in Cancer Research. Recurrent topics in F. Majois's work include Cancer Treatment and Pharmacology (13 papers), HER2/EGFR in Cancer Research (9 papers) and Breast Cancer Treatment Studies (8 papers). F. Majois is often cited by papers focused on Cancer Treatment and Pharmacology (13 papers), HER2/EGFR in Cancer Research (9 papers) and Breast Cancer Treatment Studies (8 papers). F. Majois collaborates with scholars based in Belgium, France and Australia. F. Majois's co-authors include M. Beauduin, Olivier Descamps, Bérengère Husson, Walter Feremans, Christophe Ravoet, M. Lambermont, Alain Kentos, P J Capel, D. Becquart and E. Salamon and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and European Heart Journal.

In The Last Decade

F. Majois

26 papers receiving 342 citations

Peers

Countries citing papers authored by F. Majois

Since Specialization

Citations

This map shows the geographic impact of F. Majois's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Majois with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Majois more than expected).

Fields of papers citing papers by F. Majois

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. Majois. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Majois. The network helps show where F. Majois may publish in the future.

Co-authorship network of co-authors of F. Majois

This figure shows the co-authorship network connecting the top 25 collaborators of F. Majois. A scholar is included among the top collaborators of F. Majois based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. Majois. F. Majois is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer. 2013 ·PubMed ·Arlene Chan, Pierfranco Conté, Luboš Petruželka, N. Tubiana-Mathieu, Vinod Ganju, Antonio Llombart‐Cussac, Marc Espié, F. Majois, Miguel Gil Gil, Nathalie Vaissière, G. Villanova	6
2	Activity of sunitinib in advanced malignant melanoma and its correlation with potential predictive biomarkers. 2010 ·Journal of Clinical Oncology ·Lore Decoster, Bart Neyns, Isabelle Vande Broek, Ellen Anckaert, (unknown), Johan De Mey, F. Majois, Jean‐François Baurain, Hannelore Denys, Jacques De Grève	7
3	All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial 2009 ·British Journal of Cancer ·N. Tubiana-Mathieu, Philippe Bougnoux, D. Becquart, Arlene Chan, Pierfranco Conté, F. Majois, (unknown), (unknown), Nathalie Vaissière, G. Villanova	37
4	All-oral combination of oral vinorelbine (NVBo) and capecitabine (X) in HER2-negative metastatic breast cancer (MBC): latest results of a multicenter, international phase II trial with a median follow-up of 37.7 months. 2009 ·Cancer Research ·N. Tubiana-Mathieu, (unknown), D. Becquart, A Chan, F. Majois, (unknown), (unknown), Nathalie Vaissière, G. Villanova, Pierfranco Conté	3
5	All-oral vinorelbine (NVBo) and capecitabine (X) combination for chemotherapy-naive HER2-negative metastatic breast cancer (MBC) patients: efficacy and safety in an international phase II study 2008 ·European Journal of Cancer Supplements ·N. Tubiana-Mathieu, Philippe Bougnoux, D. Becquart, (unknown), F. Majois, (unknown), (unknown), Antonio Llombart‐Cussac, G. Villanova, Pierfranco Conté	1
6	An international phase II study of an all-oral combination of oral vinorelbine (NVBo) and capecitabine (X) in HER2-negative metastatic breast cancer (MBC) 2007 ·Journal of Clinical Oncology ·N. Tubiana-Mathieu, Philippe Bougnoux, D. Becquart, Arlene Chan, F. Majois, (unknown), D. Aubert, G. Villanova, Pierfranco Conté	2
7	High-Dose Oral Medroxyprogesterone Acetate or Tamoxifen as Adjuvant Hormone Therapy for Node-Negative Early-Stage Breast Cancer: Randomized Trial with 7-Year Update 2004 ·Clinical Breast Cancer ·Christian Focan, M. Beauduin, F. Majois, Jean-Luc Canon, (unknown), D Focan-Henrard, Jean‐Pierre Lobelle	8
8	Palmar Fasciitis and Arthritis: Association with Endometrial Adenocarcinoma 2002 ·Clinical Rheumatology ·(unknown), F. Majois, C. Mitine	12
9	Adjuvant high-dose medroxyprogesterone acetate for early breast cancer: 13 years update in a multicentre randomized trial 2001 ·British Journal of Cancer ·(unknown), C. Focan, M. Beauduin, E. Salamon, Jacques De Grève, (unknown), J.P. Lobelle, F. Majois, (unknown), Jan Tytgat, Sebastian Belle, (unknown), A. Vindevoghel	27
10	P102 Adjuvant high-dose medroxyprogesterone acetate (HD-MPA) for early breast cancer. 13 years update of a multicenter randomized trial 1998 ·European Journal of Cancer ·C. Focan, M. Beauduin, E. Salamon, Jacques De Grève, (unknown), J.P. Lobelle, F. Majois, (unknown), Jan Tytgat, Sebastian Belle, (unknown), A. Vindevoghel	2
11	Clinical evidence for an engraftment syndrome associated with early and steep neutrophil recovery after autologous blood stem cell transplantation. 1996 ·PubMed ·Christophe Ravoet, Walter Feremans, Bérengère Husson, F. Majois, Alain Kentos, M. Lambermont, (unknown), P J Capel, M. Beauduin, (unknown)	73
12	Coronary artery spasm induced by 5-fluorouracil 1991 ·European Heart Journal ·(unknown), Olivier Descamps, F. Majois, (unknown), M. Beauduin	61
13	A phase I-II trial of induction chemotherapy with carboplatin and fluorouracil in locally advanced head and neck squamous cell carcinoma: a report from the UCL-Oncology Group, Belgium. 1991 ·Journal of Clinical Oncology ·V. Grégoire, M. Beauduin, Yves Humblet, Marc Hamoir, J Longueville, F. Majois, (unknown), Frédérique Rousseau, E. Salamon, André Wambersie	15
14	Experience of the Belgian Society of Medical Oncology with single-administration 5 g/m2 ifosfamide with mesna as second- or third-line therapy in advanced breast cancer 1990 ·Cancer Chemotherapy and Pharmacology ·(unknown), C. Focan, J. Michel, Martine Piccart, E. Salamon, M. Beauduin, Marie-Thérèse Closon, Elias Tueni, A. Vindevoghel, F. Majois, (unknown)	8
15	Carboplatin in combination with etoposide in inoperable non-small-cell lung cancer (NSCLC) 1990 ·Medical Oncology and Tumor Pharmacotherapy ·P. Weynants, Yves Humblet, André Bosly, Denis Schallier, (unknown), F. Majois, M. Beauduin, (unknown), Michel Symann	4
16	Adjuvant Treatment with High Dose Medroxyprogesterone Acetate in Node-Negative Early Breast Cancer A 3-year Interim Report on a Randomized Trial (I) 1989 ·Acta Oncologica ·C. Focan, A Baudoux, M. Beauduin, (unknown), (unknown), (unknown), J.P. Lobelle, E Longeval, F. Majois, (unknown), (unknown), E. Salamon, (unknown), Jan Tytgat, Sebastian Belle, Bruno Vanderlinden, (unknown), A. Vindevoghel	6
17	Carboplatin in association with etoposide and either adriamycin or epirubicin for untreated small cell lung cancer: A dose escalation study of carboplatin 1989 ·Medical Oncology and Tumor Pharmacotherapy ·Yves Humblet, P. Weynants, André Bosly, F. Majois, (unknown), Charles K. Francis, M. Beauduin, J. H. Machiels, (unknown), Luc Delaunois, Daniel Rodenstein, Chantal Doyen, J Longueville, (unknown), Denis Schallier, J Prignot, Michel Symann	14
18	Dosage Serique De La Neurone Specifique Enoease: Interet Comme Marqueur Tumoral Dij Cancer Microcellulaire Bronchique 1989 ·Acta Clinica Belgica ·P. Weynants, (unknown), F. Majois, (unknown), Ph. De Nayer	4
19	[A case of post-mastectomy lymphangiosarcoma]. 1988 ·PubMed ·(unknown), (unknown), (unknown), (unknown), F. Majois, M. Beauduin	2
20	Le traitement conservateur du cancer du sein par la technique radiochirurgicale de Jolimont 1981 ·Gyn�kologisch-geburtshilfliche Rundschau ·(unknown), M. Beauduin, J Hermans, F. Majois, (unknown)	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact